President Donald Trump signed an executive order on April 18 directing the FDA to accelerate review pathways for psychedelic-based treatments including ibogaine, while committing $50 million to related federal research. The order expands access mechanisms and outlines a faster path for approval and potential rescheduling of certain psychedelic therapies.
- The order directs the FDA to prioritize psychedelic drugs with Breakthrough Therapy designation, including through expedited review mechanisms.
- Trump announced $50 million in federal research funding to support psychedelic treatment development through HHS.
- The directive expands Right to Try access for eligible patients and calls for coordination between the FDA, DEA, and VA.
- The order instructs federal agencies to facilitate rescheduling of Schedule I substances after successful Phase 3 trials.
- FDA Commissioner Marty Makary said decisions on some psychedelic drugs could come as soon as this summer.
- FDA rejected MDMA-assisted PTSD therapy in 2024, citing trial-quality and safety concerns.
- Lobbying filings in the uploaded dataset show rising public-company activity on psychedelics: Compass Pathways ($CMPS) disclosed about $320,000 in 2025 and $220,000 in January 2026 tied to psychedelic-medicine appropriations and regulation, while Mind Medicine ($MNMD) disclosed 2024 lobbying tied to FDA/DEA psychedelic trial guidance.
- Across public-company filings, lobbying tied to psychedelic-related policy and regulation has totaled several million dollars over the past 5–10 years, reflecting growing industry engagement with federal policymakers.
Relevant Companies
- Compass Pathways ($CMPS) – Develops psychedelic-based mental health treatments and has lobbied on psychedelic research and regulatory issues.
- Mind Medicine ($MNMD) – Has lobbied on FDA and DEA policies related to psychedelic clinical trials.
Editor’s Note: This is a developing story. This article may be updated as more detail
